Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Change in Accured Expenses (2022 - 2025)

Rxo (RXO) has disclosed Change in Accured Expenses for 4 consecutive years, with $75.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 26.47% year-over-year to $75.0 million, compared with a TTM value of $2.0 million through Dec 2025, down 98.29%, and an annual FY2025 reading of $2.0 million, down 98.29% over the prior year.
  • Change in Accured Expenses was $75.0 million for Q4 2025 at Rxo, up from -$2.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $102.0 million in Q4 2024 and bottomed at -$60.0 million in Q2 2023.
  • Average Change in Accured Expenses over 4 years is $5.1 million, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses crashed 957.14% in 2023, then soared 2000.0% in 2024.
  • Year by year, Change in Accured Expenses stood at -$17.0 million in 2022, then rose by 29.41% to -$12.0 million in 2023, then soared by 950.0% to $102.0 million in 2024, then dropped by 26.47% to $75.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for RXO at $75.0 million in Q4 2025, -$2.0 million in Q3 2025, and -$56.0 million in Q2 2025.